– Dosing for first patient in PBGM01 Phase 1/2 trial anticipated in 1Q2021; initial safety and biomarker data expected mid-year 2021 –
– Phase 1/2 clinical trials for FTD-GRN and Krabbe expected to initiate in 1H21 –
– Completion of dedicated manufacturing suite achieved to ensure control of supply of company’s lead products through early commercialization – 
– Management to host conference call today at 8:30 a.m. ET –